Robert W. Baird Issues Pessimistic Forecast for Illumina (NASDAQ:ILMN) Stock Price

Illumina (NASDAQ:ILMN) had its target price decreased by Robert W. Baird from $127.00 to $90.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the life sciences company’s stock.

ILMN has been the subject of several other reports. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $130.00 to $100.00 in a research note on Monday, February 10th. Canaccord Genuity Group decreased their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. Piper Sandler increased their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Citigroup decreased their price target on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, UBS Group increased their price target on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.25.

Illumina Trading Up 0.9 %

NASDAQ:ILMN opened at $85.69 on Wednesday. The company has a 50-day moving average price of $120.36 and a 200-day moving average price of $132.17. Illumina has a 12 month low of $80.18 and a 12 month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market cap of $13.57 billion, a price-to-earnings ratio of -11.16, a P/E/G ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts predict that Illumina will post 4.51 EPS for the current year.

Institutional Trading of Illumina

A number of institutional investors have recently made changes to their positions in the stock. Probity Advisors Inc. boosted its holdings in shares of Illumina by 12.2% during the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company’s stock valued at $274,000 after acquiring an additional 224 shares during the last quarter. Siemens Fonds Invest GmbH boosted its holdings in shares of Illumina by 84.8% during the 4th quarter. Siemens Fonds Invest GmbH now owns 6,119 shares of the life sciences company’s stock valued at $818,000 after acquiring an additional 2,807 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Illumina during the 4th quarter valued at about $29,913,000. Mackenzie Financial Corp boosted its holdings in shares of Illumina by 9.5% during the 4th quarter. Mackenzie Financial Corp now owns 21,194 shares of the life sciences company’s stock valued at $2,832,000 after acquiring an additional 1,839 shares during the last quarter. Finally, North Star Asset Management Inc. boosted its holdings in shares of Illumina by 6.4% in the fourth quarter. North Star Asset Management Inc. now owns 85,604 shares of the life sciences company’s stock worth $11,439,000 after buying an additional 5,160 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.